-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

Benzinga·08/11/2026 17:30:21
语音播报
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.